Metraipolis › archive › dc_de6ae347f7f2

Placebo-associated changes in MRI-PDFF and metabolic parameters in MASLD patients from phase Ib/IIa clinical trials: implications for early-phase trial design… — Europe PMC PMID:41953202

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41953202
DOI
10.3389/fphar.2026.1782232
License (as archived)
solo-consultazione
Archived
2026-11-03T23:53:20.578Z
SHA-256 of the archived text
b43d9a4d023ecfbeca5f84fafa61905e1d7388427200ec7c137506461ea67fdd
Stable URL of this page
https://metraipolis.com/documento/dc_de6ae347f7f2

How to cite

Placebo-associated changes in MRI-PDFF and metabolic parameters in MASLD patients from phase Ib/IIa clinical trials: implications for early-phase trial design… — Europe PMC PMID:41953202 — Europe PMC (en), https://europepmc.org/article/MED/41953202 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_de6ae347f7f2 (Metraipolis archive dc_de6ae347f7f2, sha256 b43d9a4d023ecfbeca5f84fafa61905e1d7388427200ec7c137506461ea67fdd)
BibTeX
@misc{dcde6ae347f7f2,
  title = {Placebo-associated changes in MRI-PDFF and metabolic parameters in MASLD patients from phase Ib/IIa clinical trials: implications for early-phase trial design… — Europe PMC PMID:41953202},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41953202},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_de6ae347f7f2; sha256 b43d9a4d023ecfbeca5f84fafa61905e1d7388427200ec7c137506461ea67fdd},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41953202. Agents can read the archived copy with the MCP tool read_document.